Intensity Therapeutics Inc (INTS)

$0.31 +0.01 (4.15%)
Market Cap 7.37M
Revenue (ttm) 0.00
Net Income (ttm) -16.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 329,300
Avg Vol 1,371,282
Day's Range N/A - N/A
Shares Out 25.07M
Stochastic %K 36%
Beta 3.65
Analysts Sell
Price Target $4.17

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology
Sector: Healthcare
Phone: 203 221 7381
Fax: 203 557 3023
Address:
1 Enterprise Drive, Suite 430, Shelton, United States
MTC_fool
MTC_fool Jun. 26 at 2:54 PM
$INTS : were these suckers not able to close their offering yet??
0 · Reply
Lifefinder
Lifefinder Jun. 25 at 1:24 PM
$INTS maybe today …
0 · Reply
builderup
builderup Jun. 24 at 7:45 PM
Nice 2 day run. Let’s keep it going! Scaling out but still strong. Patience $CAMP $SKYE $INTS
0 · Reply
Lifefinder
Lifefinder Jun. 24 at 6:15 PM
$INTS we need good news !!!!
0 · Reply
wtfakker
wtfakker Jun. 24 at 2:53 PM
$INTS im in, you can moon now.
0 · Reply
peterbird
peterbird Jun. 24 at 4:31 AM
$INTS $2? Disclaimer: not a financial advice!!!!
1 · Reply
DaNiuBiJiaoLan
DaNiuBiJiaoLan Jun. 23 at 2:12 PM
$INTS wake up wake up.....🆙️🆙️🆙️
0 · Reply
builderup
builderup Jun. 23 at 9:44 AM
Weekly watch list… $CAMP $SKYE $INTS Weekly watchlist
1 · Reply
Sam131313
Sam131313 Jun. 22 at 8:33 PM
$INTS Has warrants at .85 and till dec to be in compliance
1 · Reply
Sam131313
Sam131313 Jun. 18 at 8:02 PM
$INTS Uoneo
0 · Reply
Latest News on INTS
Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 11:46 PM EDT - 15 days ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 4:06 PM EDT - 15 days ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

Jun 11, 2025, 8:30 AM EDT - 15 days ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 29, 2025, 8:00 AM EDT - 4 weeks ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 28, 2025, 8:00 AM EDT - 4 weeks ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 4:06 PM EDT - 6 weeks ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

May 6, 2025, 8:00 AM EDT - 7 weeks ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Apr 25, 2025, 8:00 AM EDT - 2 months ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Mar 13, 2025, 4:07 PM EDT - 3 months ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 28, 2025, 8:00 AM EST - 5 months ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Jan 10, 2025, 8:00 AM EST - 5 months ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Dec 12, 2024, 8:00 AM EST - 7 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 21, 2024, 8:00 AM EST - 7 months ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 18, 2024, 8:00 AM EST - 7 months ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:06 PM EST - 8 months ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Nov 8, 2024, 8:01 AM EST - 8 months ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Oct 31, 2024, 9:00 AM EDT - 8 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:00 AM EDT - 10 months ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:19 PM EDT - 11 months ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 15, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

May 14, 2024, 9:38 AM EDT - 1 year ago

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 10, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:08 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 4:09 PM EDT - 1 year ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Mar 14, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Feb 21, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Jan 3, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 12, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Dec 8, 2023, 8:30 AM EST - 1 year ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Dec 1, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Nov 13, 2023, 8:01 AM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Nov 2, 2023, 7:01 AM EDT - 1 year ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Sep 7, 2023, 8:01 AM EDT - 1 year ago

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:01 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

Aug 14, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

Aug 7, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds

Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Jul 5, 2023, 4:15 PM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

U.S. IPO Weekly Recap: Sizable Deals Close Out The Q2 IPO Market, Led By Thrift Store Savers

Jul 1, 2023, 3:15 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Sizable Deals Close Out The Q2 IPO Market, Led By Thrift Store Savers

AENT FIHL GENK KGS SRFM SVV VTMX

Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Jun 29, 2023, 8:00 PM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

Jun 6, 2023, 7:35 AM EDT - 2 years ago

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Jun 3, 2023, 8:00 AM EDT - 2 years ago

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Dec 8, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

Nov 18, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers

Nov 11, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers

Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers

Nov 10, 2022, 7:01 AM EST - 2 years ago

Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers

Intensity Therapeutics Finalizes Terms For $10 Million IPO

Sep 22, 2022, 9:30 AM EDT - 3 years ago

Intensity Therapeutics Finalizes Terms For $10 Million IPO

MTC_fool
MTC_fool Jun. 26 at 2:54 PM
$INTS : were these suckers not able to close their offering yet??
0 · Reply
Lifefinder
Lifefinder Jun. 25 at 1:24 PM
$INTS maybe today …
0 · Reply
builderup
builderup Jun. 24 at 7:45 PM
Nice 2 day run. Let’s keep it going! Scaling out but still strong. Patience $CAMP $SKYE $INTS
0 · Reply
Lifefinder
Lifefinder Jun. 24 at 6:15 PM
$INTS we need good news !!!!
0 · Reply
wtfakker
wtfakker Jun. 24 at 2:53 PM
$INTS im in, you can moon now.
0 · Reply
peterbird
peterbird Jun. 24 at 4:31 AM
$INTS $2? Disclaimer: not a financial advice!!!!
1 · Reply
DaNiuBiJiaoLan
DaNiuBiJiaoLan Jun. 23 at 2:12 PM
$INTS wake up wake up.....🆙️🆙️🆙️
0 · Reply
builderup
builderup Jun. 23 at 9:44 AM
Weekly watch list… $CAMP $SKYE $INTS Weekly watchlist
1 · Reply
Sam131313
Sam131313 Jun. 22 at 8:33 PM
$INTS Has warrants at .85 and till dec to be in compliance
1 · Reply
Sam131313
Sam131313 Jun. 18 at 8:02 PM
$INTS Uoneo
0 · Reply
grock55
grock55 Jun. 18 at 7:10 PM
$INTS
0 · Reply
grock55
grock55 Jun. 18 at 7:10 PM
$INTS only 500 watchers???? This stock has great future forecast from analysts they saying 1000% return with a strong buy do your research now before it breaks out
0 · Reply
MTC_fool
MTC_fool Jun. 18 at 4:54 PM
$INTS : This company is a strong take over candidate!! Multiple $$$S
0 · Reply
mr_bowjangles
mr_bowjangles Jun. 18 at 3:27 PM
$INTS
0 · Reply
Sam131313
Sam131313 Jun. 18 at 3:14 PM
$INTS
0 · Reply
Sam131313
Sam131313 Jun. 18 at 2:58 PM
$INTS 12–3-25 to regain compliance
0 · Reply
Sam131313
Sam131313 Jun. 18 at 2:56 PM
$INTS Warrants n offering capabilities at .85. Lfg
0 · Reply
Sam131313
Sam131313 Jun. 18 at 2:39 PM
$INTS In for a swing
0 · Reply
Holmes700R
Holmes700R Jun. 17 at 6:05 PM
$INTS 3.9million market cap… someone must know something for it to be that low
0 · Reply
Holmes700R
Holmes700R Jun. 17 at 6:01 PM
$INTS the thing that gets me here is if they had good news, surely they would announce it before the offering then release and offering to get more money at a higher price… this doesn’t concern me that they might not have the good news
1 · Reply
Holmes700R
Holmes700R Jun. 17 at 5:44 PM
$INTS what price was the offering at per share?
1 · Reply
theshortsqueezer2022
theshortsqueezer2022 Jun. 16 at 9:26 PM
$INTS offering has been closed. Now it’s time to drop good news.
1 · Reply